Meet our network

Ovo Labs develops therapeutics that improve egg quality to increase the success of in vitro fertilization (IVF) and give more couples the chance to experience the joy of parenthood. By addressing the biological causes of age-related decline in egg quality, the company aims to help women conceive with success rates closer to those seen at a younger reproductive age. Built on nearly two decades of world-leading research in human egg biology, Ovo Labs is currently advancing several first-in-class therapeutic candidates through preclinical development.

Redesigning drug development by continuous real-time & high-content analysis

The development and testing of new drugs through to approval are very cost-intensive. In addition, new regulatory provisions are intended to reduce the number of animal experiments in future. The biotech startup myotwin uses stem cell-based heart muscle tissue in a specially developed measurement infrastructure. This allows a much earlier and comprehensive insight into the human reaction to an active ingredient. As a result, new active substances can be tested in preclinical trials without animal testing and safety in clinical trials can be increased. myotwin also uses its extensive data to create a digital twin of the human heart muscle in order to offer services in the field of predictive drug development in the future.

Pioneering novel RNA-based therapeutics

At Avocet Bio, our mission is clear: we want to break new ground by using our platform technology of RNA modulation as key therapeutic approach for a variety of diseases.

As a biotech startup, we address some of the most pressing global health challenges, including respiratory viral infections, while expanding the potential of RNA modulation to other areas of medicine.

Our long-term goal is to build a diverse portfolio of RNA-based therapeutics that address existing treatment gaps and offer new, more effective solutions for patients.

Repairon Immuno develops scalable, next-generation cell therapies based on iPSC technology to enhance existing and future CART cell therapies. The goal is to replace personalized and costly custom-made treatments with off-the-shelf cell therapies, making treatments faster, more cost-effective, and more widely accessible. The technology is intended for the causal treatment of autoimmune diseases and cancer.

brainQr makes disordered proteins druggable

brainQr Therapeutics is developing next-generation therapies for major human diseases by targeting disordered proteins, a vast and previously largely undruggable class of biomolecules. Our mission is to harness cutting-edge scientific innovation to pioneer novel treatment strategies that address urgent unmet medical needs. brainQr’s AI-IDP platform enables breakthrough therapies for dynamic disordered proteins, unlocking new possibilities in neurodegeneration and oncology.

Noselab has developed a proprietary platform that makes biomarker signatures of central nervous system (CNS) diseases accessible through a previously untapped biological gateway: the brain–nose interface (BNI) and nasal fluid. By enabling direct, minimally invasive access to CNS-related molecular signals, Noselab is driving a paradigm shift in understanding, diagnosing, monitoring, and treating brain diseases.

Focused on advanced diagnostic and analytics technologies for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and other dementias, PhalanxNeuro leverages a proprietary platform that mimics the protein “seeding” mechanisms underlying these conditions. This approach enables the precise detection of disease‑specific biomarkers, subtypes, and co‑pathologies, supporting earlier and more accurate patient stratification. As a result, the company advances precision medicine approaches and the development of personalized treatments.

Viacure is developing a novel antibody-based therapy targeting the insulin-inhibiting receptor “Inceptor.” By restoring the function of insulin-producing beta cells, Viacure aims to tackle type 2 diabetes at its root, shifting treatment from symptom control to true disease intervention.

Cultimate Foods creates a game-changing ingredient based on cultivated fat in a sustainable and ethical way.
Their unique solution enriches plant-based meat alternatives with authentic taste, mouthfeel, and texture. They believe that the future of meat is hybrid – a combination of plant-based proteins and their fat alternative product.

We are building the world’s first biotechnological Direct Air Capture (DAC) system with the goal to to capture 1% of the global CO2 emissions by 2035!

Leveraging novel membranes and enzymes significantly reduces the energy consumption by lowering the conventional Direct Air Capture reaction temperature from up to 900°C to room temperature and avoiding active air intake. This enables massive cost savings and a sustainable reduction of CO2 in the atmosphere. 

Using the most modern equipment and S1 lab as well as the makerspace we found the perfect place at the Life Science Factory to develop our biotech hardware solution.

Digity is a hand-focused technology startup specializing in automated processes to equip the human hand with exoskeletons. Our hands define how we interact with the world, and our mission is therefore to ensure that they are always healthy, protected, and productive. Our patents and a digital backend technology enable us to adapt our exoskeletons to different application areas. Our starting point, ARTUS, addresses occupational safety and finger ergonomics in manual tasks in industry and the skilled trades. The interdisciplinary team from engineering sciences, orthopedic technology, and business administration emerged from an EXIST research transfer program and aims to build a market leader from Göttingen that provides real solutions for hand-related challenges.